Non-alcoholic fatty liver disease: a narrative review of genetics
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver diseases worldwide. It encompasses a spectrum of disorders ranging from isolated hepatic steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. One of the key challenges in NAFLD is identifying which patients will progress. Epidemiological and genetic studies indicate a strong pattern of heritability that may explain some of the variability in NAFLD phenotype and risk of progression. To date, at least three common genetic variants in the PNPLA3, TM6SF2, and GCKR genes have been robustly linked to NAFLD in the population. The function of these genes revealed novel pathways implicated in both the development and progression of NAFLD. In addition, candidate genes previously implicated in NAFLD pathogenesis have also been identified as determinants or modulators of NAFLD phenotype including genes involved in hepatocellular lipid handling, insulin resistance, inflammation, and fibrogenesis. This article will review the current understanding of the genetics underpinning the development of hepatic steatosis and the progression of NASH. These newly acquired insights may transform our strategy to risk-stratify patients with NAFLD and to identify new potential therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 2×
“In addition to ROS activation, NASH is associated with activation of the innate immune response due to sterile inflammation and gut-derived bacterial products([87]).”
BackgroundKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 3×
“[19] Kozlitina J, Smagris E, Stender S, et al.”
BackgroundSpeliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 3×
“Most recently, exome-wide sequencing has identified the rs72613567:TA variant within hydroxysteroid 17beta dehydrogenase 13 (HSD17B13), which was associated with a decreased risk of alcoholic liver disease, NASH, alcoholic cirrhosis, and NASH cirrhosis([53]).”
BackgroundInfluentialA 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 2×
“Similar to the PNPLA3 I148M variant, the TM6SF2 E1267K variant not only increases the risk of steatosis, but has also been associated with increased risk of progressive liver disease and fibrosis([20]).”
BackgroundResultBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · cited 2×
“Loss-of-function mutations within PCKS9 similarly result in decreased serum cholesterol, but do not seem to be associated with increased hepatic triglycerides([58]).”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Beer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., & Gloyn, A. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp357 · Cited by 401
A feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 1×
“The PNPLA3 gene encodes a 481-amino acid membrane protein located in the endoplasmic reticulum and lipid droplets in hepatocytes and hepatic stellate cells (HSCs)([23]).”
BackgroundPnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K. V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Hepatology · doi:10.1002/hep.27242 · Cited by 379
Mahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., & van't Hooft, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323785111 · Cited by 369 · cited 2×
“The TM6SF2 gene encodes a 351-amino acid protein with seven transmembrane domains expressed in the liver and intestine in humans([39]).”
BackgroundHepatocyte senescence predicts progression in non-alcohol-related fatty liver disease
Aravinthan, A., Scarpini, C., Tachtatzis, P., Verma, S., Penrhyn-Lowe, S., Harvey, R., Davies, S. E., Allison, M., Coleman, N., & Alexander, G. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.031 · Cited by 326
BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Ruddell, R. G., Hoang‐Le, D., Barwood, J. M., Rutherford, P. S., Piva, T. J., Watters, D. J., Santambrogio, P., Arosio, P., & Ramm, G. A. (2009) · Hepatology · doi:10.1002/hep.22716 · Cited by 298
Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C., & Hobbs, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719955 · Cited by 226
Telomerase gene mutations are associated with cirrhosis formation
Hartmann, D., Srivastava, U., Thaler, M., Kleinhans, K. N., N'Kontchou, G., Scheffold, A., Bauer, K., Kratzer, R. F., Kloos, N., Katz, S.-F., et al. (2011) · Hepatology · doi:10.1002/hep.24217 · Cited by 173
Musso, G., Cassader, M., De Michieli, F., Rosina, F., Orlandi, F., & Gambino, R. (2012) · Hepatology · doi:10.1002/hep.25739 · Cited by 126
Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism
Raimondo, A., Rees, M. G., & Gloyn, A. L. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000155 · Cited by 118 · cited 1×
“GCKR plays an important role in hepatic glucose uptake through regulating the partitioning of GCK (glucokinase) between the cytosol and nucleus([42]).”
BackgroundGuettier, J.-M., Georgopoulos, A., Tsai, M. Y., Radha, V., Shanthirani, S., Deepa, R., Gross, M., Rao, G., & Mohan, V. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1338 · Cited by 108 · cited 1×
“[68] Guettier JM, Georgopoulos A, Tsai MY, et al.”
BackgroundApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100 · cited 1×
“Apolipoprotein C3 (apoC3) is a major constituent of VLDL particles and promotes triglyceride-rich VLDL assembly and secretion([66]).”
BackgroundFatty Acid Flippase Activity of UCP2 Is Essential for Its Proton Transport in Mitochondria
Berardi, M. J., & Chou, J. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.004 · Cited by 76 · cited 1×
“Uncoupling protein 2 (UCP2) regulates mitochondrial redox status by uncoupling oxidative phosphorylation([84]).”
BackgroundApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70 · cited 1×
“[67] Olivieri O, Stranieri C, Bassi A, et al.”
Background
Cited by
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., et al. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003149 · Cited by 97
“Reassuringly, several of the features that ranked highest have been previously described for their association with liver fat content or closely related traits; these include PNPLA3 gene variants [44,51], fetal liver tyrosine kinase-3 (FLT3) transcripts [52], IGFBP1 [53–55] and lipoprotein lipase (Lpl) [56] proteins,…”
BackgroundEffects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144079 · Cited by 81
“This single nucleotide variant reduces expression of the TM6SF2 protein by 46% in liver cells (7), and its prevalence is around 7% in Caucasian populations (8).”
Background
Metadata
- Authors
- Christopher, J., Zemin, Y., & Z., G.
- Venue
- The Journal of Biomedical Research
- Publisher
- Journal of Biomedical Research
- Published
- 2018
- Volume
- 32
- Issue
- 6
- Pages
- 389
- ISSN
- 1674-8301 (ISSN-L)
- OpenAlex
- W2909886360
- Cited by
- 45
- References
- 26
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.